Literature DB >> 6690169

Mephenytoin hydroxylation deficiency: kinetics after repeated doses.

A Küpfer, P Desmond, R Patwardhan, S Schenker, R A Branch.   

Abstract

Deficient aromatic hydroxylation of S-mephenytoin was observed in an index subject during a kinetic study of stereoselective metabolism of mephenytoin. A genetic basis for this defect was suggested by decreased urinary recovery of 3-methyl-5-(4-hydroxyphenyl)-5-ethylhydantoin (4-OH-M) in the 24 hr after oral racemic mephenytoin in two brothers of the propositus. The parents and a third brother had urinary recoveries of 4-OH-M of the same order as in a group of 20 normal subjects. The kinetic implications of this defect were studied in the index subject and compared with four normal subjects after a single oral dose of differentially radiolabeled pseudoracemic mephenytoin (5 microCi of 14C-S-mephenytoin, 45 microCi of H3-R-mephenytoin, and 11.5 mumol/kg of both S- and R-mephenytoin) followed by single oral doses of 1.4 mmol of unlabeled racemic mephenytoin daily the next 4 days. In normal subjects, there was substrate stereoselective metabolism with the S-enantiomer rapidly excreted as 4-OH-M and the R-enantiomer slowly excreted as 5-phenyl-5-ethylhydantoin (PEH). Stereoselective metabolism persisted during repeated dosing. In the hydroxylation-deficient subject, there was no evidence of stereoselective metabolism, recovery of 4-OH-M was low, and both enantiomers were slowly excreted, predominantly as PEH. Plasma PEH concentrations and urinary PEH excretion rates were approximately twice that in normal subjects. Thus a genetic deficiency in ability to hydroxylate S-mephenytoin results in the S-enantiomer metabolization by the alternate route of demethylation to PEH that cumulates, thereby, in comparison to the normal, effectively doubling the dose of total hydantoin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6690169     DOI: 10.1038/clpt.1984.5

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

1.  Caution in the use of a 100 mg dose of racemic mephenytoin for phenotyping southeastern Oriental subjects.

Authors:  R Setiabudy; K Chiba; M Kusaka; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

Review 2.  Polymerase chain reaction and its potential as a pharmacokinetic tool.

Authors:  M H Heim
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

Review 3.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

Review 4.  Stereoselectivity in pharmacokinetics: a general theory.

Authors:  R H Levy; A V Boddy
Journal:  Pharm Res       Date:  1991-05       Impact factor: 4.200

5.  The induction effect of rifampicin on activity of mephenytoin 4'-hydroxylase related to M1 mutation of CYP2C19 and gene dose.

Authors:  H J Feng; S L Huang; W Wang; H H Zhou
Journal:  Br J Clin Pharmacol       Date:  1998-01       Impact factor: 4.335

6.  Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies.

Authors:  Y Zhang; R A Blouin; P J McNamara; J Steinmetz; P J Wedlund
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

7.  Family studies of mephenytoin hydroxylation deficiency.

Authors:  T Inaba; M Jurima; W Kalow
Journal:  Am J Hum Genet       Date:  1986-05       Impact factor: 11.025

Review 8.  The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications.

Authors:  Ulrich Klotz
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 9.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

10.  Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11β-hydroxysteroid dehydrogenase type-1 inhibitor BMS-823778.

Authors:  Yaofeng Cheng; Lifei Wang; Lisa Iacono; Donglu Zhang; Weiqi Chen; Jiachang Gong; William Griffith Humphreys; Jinping Gan
Journal:  Br J Clin Pharmacol       Date:  2017-10-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.